Hutchison China MediTech Limited (HCM) News

Hutchison China MediTech Limited (HCM): $18.73

0.01 (+0.05%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add HCM to Watchlist
Sign Up

Industry: China

Industry

B

Ranked

#18 of 40

in industry

Filter HCM News Items

HCM News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

HCM News Highlights

  • For HCM, its 30 day story count is now at 3.
  • Over the past 12 days, the trend for HCM's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about HCM are AIM, DEC and DRUG.

Latest HCM News From Around the Web

Below are the latest news stories about HUTCHMED (CHINA) LTD that investors may wish to consider to help them evaluate HCM as an investment opportunity.

HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Terms

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that under the 2023 simple renewal mechanism of the China National Healthcare Security Administration (“NHSA”), on January 1, 2024 the updated National Reimbursement Drug List (“NRDL”) will continue to include ELUNATE® (fruquintinib) and SULANDA® (surufatinib) at the same terms as the current two-year agreement. Mr Hong Chen, Se

Yahoo | December 13, 2023

HUTCHMED Announces that it has Completed Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China

HONG KONG, Shanghai and FLORHAM Park, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (Nasdaq/AIM:​HCM, HKEX:​13) (“HUTCHMED”) today announces that it has completed enrollment of its Phase II/III trial of fruquintinib in combination with sintilimab as second-line treatment for locally advanced or metastatic renal cell carcinoma (“RCC”) in China. The study is a randomized, open-label, active-controlled study to evaluate the efficacy and safety of fruquintinib in combination with

Yahoo | December 13, 2023

HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Nov. 30, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today highlights that new clinical data from several ongoing studies with HUTCHMED investigational drug candidates fruquintinib, surufatinib and HMPL-295, which will be presented at the upcoming European Society for Medical Oncology (“ESMO”) Asia Congress, taking place on December 1-3, 2023 in Singapore, and the ESMO Immuno-Oncology Congress, t

Yahoo | December 1, 2023

Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing

Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.comNEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Deutsche Bank Depositary Receipts Virtual Investor Conference (“dbVIC”) held on November 8th and 9th are now available for online viewing. REGISTER NOW AT: https://bit.ly/3SyFOaq The company presentations will be available 24/7 for 90 days. Nove

Yahoo | November 10, 2023

HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

— FRUZAQLA is the first targeted therapy approved in the U.S. for metastatic colorectal cancer regardless of biomarker status or prior types of therapies in more than a decade — — U.S. approval of FRUZAQLA triggers first milestone payment from Takeda of US$35 million and royalties on net sales — HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (Nasdaq/AIM:​HCM, HKEX:​13) (“HUTCHMED”) today announced that its partner Takeda received app

Yahoo | November 9, 2023

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts

Virtual Investor Conference on November 8th and 9th, 2023NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Wednesday, November 8 and Thursday, November 9, featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the US. Representatives from participating companies based in Australia, China, France, Germany, Greece, Hong Kong, Netherla

Yahoo | November 1, 2023

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 8th and 9th, 2023

NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Wednesday, November 8 and Thursday, November 9, featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the US. Representatives from participating companies based in Australia, China, France, Germany, Greece, Hong Kong, Netherlands, Philippines and Taiwan will respond to questions dur

Yahoo | November 1, 2023

HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2023

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 16, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated clinical data from several ongoing studies of fruquintinib, in combination with chemotherapies and/or immunotherapies, will be presented at the upcoming European Society for Medical Oncology (“ESMO”) Congress 2023, taking place on October 20-24, 2023 in Madrid, Spain. Details of the presentations are as foll

Yahoo | October 16, 2023

Decoding HUTCHMED (China) Ltd (HCM)'s Performance Potential: A Deep Dive into Key Metrics

Unraveling the Factors That Could Limit HUTCHMED (China) Ltd's Future Growth

Yahoo | October 10, 2023

Ray Dalio on Potential US-China War and Rise of China

In this article, we discuss Ray Dalio on potential US China war and rise of China. If you want to skip our detailed discussion on the US China war and rise of China, head directly to Top 5 Chinese Stocks Bridgewater Associates is Selling. America’s position as a globally dominant force is under threat. Divisive politics, […]

Yahoo | October 5, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!